Abbott reported FY 2025 results showing operating margin of 18.2%, up from 16.3% in FY 2024. Gross profit margin rose to 52.6% of net sales in FY 2025 from 50.9% in FY 2024. Net interest expense declined to USD 185 million in FY 2025 from USD 215 million in FY 2024, while other income, net was USD 548 million in FY 2025 versus USD 376 million in FY 2024. Net cash from operating activities increased to USD 9.6 billion in FY 2025 from USD 8.6 billion in FY 2024. Abbott ended FY 2025 with cash and cash equivalents and short-term investments of USD 8.9 billion and long-term debt of USD 12.9 billion. By business, Medical Devices sales increased 12.6% in FY 2025 versus FY 2024, while Diagnostic Products sales fell 4.3% and Nutritional Products sales were up 0.4%; Established Pharmaceutical Products sales rose 6.6%. In Diabetes Care, continuous glucose monitoring sales totaled USD 7.6 billion in FY 2025. COVID-19 testing-related sales continued to decline, totaling USD 297 million in FY 2025 versus USD 747 million in FY 2024. Corporate updates included a definitive agreement signed on Nov. 19, 2025 for Abbott to acquire Exact Sciences for USD 105 per share in cash, valuing equity at about USD 21 billion and enterprise value at about USD 23 billion, with financing contemplating absorption of about USD 1.8 billion of net debt; Abbott also secured a 364-day senior unsecured bridge term loan commitment of up to USD 20 billion. Abbott declared FY 2025 dividends of USD 2.40 per share, and repurchased USD 604 million of shares in FY 2025, with USD 6.7 billion remaining under its 2024 repurchase program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-010185), on February 20, 2026, and is solely responsible for the information contained therein.